130,464 Shares in Progyny, Inc. (NASDAQ:PGNY) Acquired by Quantbot Technologies LP

Quantbot Technologies LP purchased a new stake in Progyny, Inc. (NASDAQ:PGNY) during the third quarter, Holdings Channel reports. The firm purchased 130,464 shares of the company’s stock, valued at approximately $2,187,000.

Several other hedge funds have also recently bought and sold shares of the stock. Hsbc Holdings PLC grew its holdings in shares of Progyny by 703.9% in the 2nd quarter. Hsbc Holdings PLC now owns 46,475 shares of the company’s stock worth $1,328,000 after purchasing an additional 40,694 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Progyny by 3.0% during the second quarter. Bank of New York Mellon Corp now owns 756,228 shares of the company’s stock worth $21,636,000 after buying an additional 22,012 shares during the last quarter. Kestrel Investment Management Corp bought a new stake in Progyny during the second quarter worth about $5,005,000. Farallon Capital Management LLC increased its holdings in shares of Progyny by 120.8% during the second quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company’s stock worth $37,436,000 after buying an additional 715,900 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS raised its stake in shares of Progyny by 15.7% in the third quarter. Kornitzer Capital Management Inc. KS now owns 976,501 shares of the company’s stock valued at $16,366,000 after acquiring an additional 132,672 shares during the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Stock Performance

PGNY opened at $15.48 on Friday. The company has a fifty day moving average price of $15.86 and a two-hundred day moving average price of $22.35. The firm has a market capitalization of $1.32 billion, a PE ratio of 26.69, a P/E/G ratio of 1.82 and a beta of 1.44. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $42.08.

Progyny (NASDAQ:PGNY) last released its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.26). The company had revenue of $286.63 million during the quarter, compared to analyst estimates of $296.85 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.16 EPS. Equities analysts forecast that Progyny, Inc. will post 0.58 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on PGNY shares. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price target on shares of Progyny in a research report on Tuesday, October 1st. JPMorgan Chase & Co. decreased their target price on Progyny from $31.00 to $22.00 and set an “overweight” rating on the stock in a report on Thursday, September 19th. Canaccord Genuity Group cut their price target on Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a report on Wednesday, November 13th. Leerink Partners decreased their price objective on shares of Progyny from $25.00 to $21.00 and set a “market perform” rating on the stock in a report on Thursday, September 19th. Finally, Bank of America dropped their target price on shares of Progyny from $22.00 to $21.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $25.42.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.